Enanta Pharmaceuticals (ENTA) Asset Utilization Ratio (2013 - 2026)
Enanta Pharmaceuticals posted quarterly Asset Utilization Ratio of 0.21 for Q1 2026, up 11.94% year-on-year from 0.19 in Q1 2025, and down 2.12% on a QoQ basis from 0.22 in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 14 years of Asset Utilization Ratio data on file, last reported at 0.21 in Q1 2026.
- For the quarter ending Q1 2026, Asset Utilization Ratio rose 11.94% year-over-year to 0.21; the trailing twelve-month figure through Mar 2026 stood at 0.21 (up 11.94% YoY), and the FY2025 full-year result was 0.2, up 23.26% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 0.21, down from 0.22 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.24 in Q1 2023 and bottomed at 0.17 in Q4 2023.
- The 5-year median for Asset Utilization Ratio is 0.21 (2025), against an average of 0.2.
- The widest annual swing landed in 2024, when Asset Utilization Ratio retreated 28.14%; it then increased 28.74% in 2025.
- A 5-year view of Asset Utilization Ratio shows it stood at 0.23 in 2022, then dropped by 27.22% to 0.17 in 2023, then gained by 11.09% to 0.18 in 2024, then rose by 19.55% to 0.22 in 2025, then fell by 2.12% to 0.21 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.21 (Q1 2026), 0.22 (Q4 2025), and 0.22 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | 0.21 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.21 |
| Dec 31, 2025 | 0.22 |
| Sep 30, 2025 | 0.22 |
| Jun 30, 2025 | 0.21 |
| Mar 31, 2025 | 0.19 |
| Dec 31, 2024 | 0.18 |
| Sep 30, 2024 | 0.17 |
| Jun 30, 2024 | 0.18 |
| Mar 31, 2024 | 0.17 |
| Dec 31, 2023 | 0.17 |
| Sep 30, 2023 | 0.17 |
| Jun 30, 2023 | 0.20 |
| Mar 31, 2023 | 0.24 |
| Dec 31, 2022 | 0.23 |
| Sep 30, 2022 | 0.23 |
| Jun 30, 2022 | 0.23 |
| Mar 31, 2022 | 0.22 |
| Dec 31, 2021 | 0.21 |
| Sep 30, 2021 | 0.22 |
| Jun 30, 2021 | 0.21 |
| Mar 31, 2021 | 0.20 |
| Dec 31, 2020 | 0.21 |
| Sep 30, 2020 | 0.25 |
| Jun 30, 2020 | 0.29 |
| Mar 31, 2020 | 0.34 |
| Dec 31, 2019 | 0.38 |
| Sep 30, 2019 | 0.43 |
| Jun 30, 2019 | 0.47 |
| Mar 31, 2019 | 0.51 |
| Dec 31, 2018 | 0.55 |
| Sep 30, 2018 | 0.52 |
| Jun 30, 2018 | 0.59 |
| Mar 31, 2018 | 0.48 |
| Dec 31, 2017 | 0.39 |
| Sep 30, 2017 | 0.34 |
| Jun 30, 2017 | 0.14 |
| Mar 31, 2017 | 0.17 |
| Dec 31, 2016 | 0.18 |
| Sep 30, 2016 | 0.31 |
| Jun 30, 2016 | 0.32 |
| Mar 31, 2016 | 0.31 |
| Dec 31, 2015 | 0.50 |
| Sep 30, 2015 | 0.67 |
| Jun 30, 2015 | 0.62 |
| Mar 31, 2015 | 0.78 |
| Dec 31, 2014 | 0.67 |
| Sep 30, 2014 | 0.30 |
| Jun 30, 2014 | 0.35 |
| Mar 31, 2014 | 0.06 |
| Dec 31, 2013 | 0.04 |
| Sep 30, 2013 | 0.27 |
| Jun 30, 2013 | 0.27 |